Pharmacoeconomic Analysis Of Abrocitinib In Patients With Severe Atopic Dermatitis Versus Systemic Treatments In Spain
Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by itchy, painful, and dry skin. Despite the great number of available therapies, economic evaluations are needed to provide evidence on their cost-efficiency to assist the National Health System (NHS) in decision-making. The objective of this study is to evaluate the cost-effectiveness of abrocitinib (200mg) […]
The relevance of Insomnia in relation to other high-impact pathologies. A systematic Literature Review
Systematic literature review conducted in pubmed/Medline in order to identify studies linking insomnia with other high impact diseases (COVID-19, cancer survivors, metabolic disease, neurodegenerative diseases and mental illness. A total of 16 publications were included. The results of the study show that insomnia is related to the development of several high-impact diseases. Early identification and […]
Loss of productivity, use of healthcare resources and cost associated with insomnia
Cross-sectional observational study based on an electronic questionnaire aimed at people with sleep problems who meet the criteria for chronic insomnia. The results show that insomnia is an under-diagnosed disease that leads to a loss of productivity and is strongly linked to presenteeism and costs to be paid by the patient. Proper diagnosis and treatment […]
First-line therapeutic management of relapsing-remitting multiple sclerosis: a survey of Spanish neurologists
This study describes the results of a neurologist survey to provide evidence on current therapeutic management and decision-making in managing mild/moderate relapsing-remitting multiple sclerosis in Spanish clinical practice.
Changing Landscape of Orphan Drug Reimbursement – Evidence From EU-4 and England
Germany continuously provides the most robust patient access to ODs, wide access to ODs is maintained in France despite an increased percentage of ODs still in the price negotiation due to the Early Access programme. The largest improvement can be seen in Italy which corresponds to the legislative changes in the pricing negotiation process and […]
Digital Health – Where Do We Stand From a Market Access Perspective in the EU-4 and the UK?
Although there are similarities between the EU4 + UK for the market access of digital health applications, processes vary between countries. As it can be seen in Germany, an improved pathway through a fast-track path can lead to faster and broader market access to patients.
Innovation Value Framework – Evidence From EU-4 and UK
It is important to implement transparency procedures in terms of the value definition criteria used by HTA organisations.
Patient-Reported Outcomes Measures para el seguimiento del paciente con asma grave. Consenso de expertos y pacientes
This study aimed to reach a consensus on the most appropriate and feasible PROMs to assess, in clinical practice, the most relevant PROs for the follow-up of severe asthma from the perspective of the patient and the healthcare professional. This work, in particular, focuses on the results of the Delphi survey and the possible barriers […]
Consenso de expertos sobre los patient reported outcomes y sus instrumentos de recogida para el seguimiento del paciente con asma grave
This study aimed to reach a consensus on the most relevant PROs and PROMs for the follow-up of severe asthma in Spanish clinical practice from the perspective of the patient and the healthcare professional. of the patient and the healthcare professional. In particular, this study focuses on the prioritisation of the use of PROMs in […]
Patient reported outcomes measures for patients with rheumatoid arthritis: patterns of use among spanish rheumatologists and barriers for their implementation in routine care
The pattern of use of the patient-reported outcomes measures (PROMs) proposed by ICHOM among rheumatologists in routine care and potential barriers that could hinder their implementation.
